Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone

OBJECTIVE: Somapacitan is a long‐acting, reversible albumin‐binding growth hormone (GH) derivative in development. This study aimed to evaluate the safety and efficacy of once‐weekly somapacitan versus daily GH over 52 weeks in Japanese patients with adult growth hormone deficiency (AGHD). DESIGN: P...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Endocrinol (Oxf)
Egile Nagusiak: Otsuka, Fumio, Takahashi, Yutaka, Tahara, Shigeyuki, Ogawa, Yoshihisa, Højby Rasmussen, Michael, Takano, Koji
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689735/
https://ncbi.nlm.nih.gov/pubmed/32603494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cen.14273
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak